Found 9822 bookmarks
Newest
Identification of Antimicrobial-Resistant Zoonotic Bacteria in Swine Production: Implications from the One Health Perspective - PubMed
Identification of Antimicrobial-Resistant Zoonotic Bacteria in Swine Production: Implications from the One Health Perspective - PubMed
Antimicrobial resistance poses a major threat to global health and food security and is primarily driven by antimicrobial use in human and veterinary medicine. Understanding its epidemiology at farm level is crucial for effective control measures. Despite the significant reduction in antibiotic use …
·pubmed.ncbi.nlm.nih.gov·
Identification of Antimicrobial-Resistant Zoonotic Bacteria in Swine Production: Implications from the One Health Perspective - PubMed
Chemical genetic analysis of enoxolone inhibition of C. difficile toxin production reveals adenine deaminase and ATP synthase as anti-virulence targets - PubMed
Chemical genetic analysis of enoxolone inhibition of C. difficile toxin production reveals adenine deaminase and ATP synthase as anti-virulence targets - PubMed
Toxins TcdA and TcdB are the main virulence factors of Clostridioides difficile, a leading cause of hospital-acquired diarrhea. Despite their importance, there is a significant knowledge gap of druggable targets for inhibiting toxin production. To address this, we screened non-antibiotic phytochemic …
·pubmed.ncbi.nlm.nih.gov·
Chemical genetic analysis of enoxolone inhibition of C. difficile toxin production reveals adenine deaminase and ATP synthase as anti-virulence targets - PubMed
Impact of Clostridium difficile Infection Versus Colonization on Postoperative Outcomes After Oncological Colorectal Surgery: An Observational Single-Center Study With Propensity Score Analysis - PubMed
Impact of Clostridium difficile Infection Versus Colonization on Postoperative Outcomes After Oncological Colorectal Surgery: An Observational Single-Center Study With Propensity Score Analysis - PubMed
HA-CDI is associated with a higher risk of anastomotic leak after oncological colorectal surgery, while asymptomatic CDC do not have higher morbidity and may be operated electively, under standard CD treatment.
·pubmed.ncbi.nlm.nih.gov·
Impact of Clostridium difficile Infection Versus Colonization on Postoperative Outcomes After Oncological Colorectal Surgery: An Observational Single-Center Study With Propensity Score Analysis - PubMed
Clostridium Diagnostics Market Key Trends, Challenges, and Growth Forecasts from 2024 to 2032 | Taiwan News | Sep. 30, 2024 10:53
Clostridium Diagnostics Market Key Trends, Challenges, and Growth Forecasts from 2024 to 2032 | Taiwan News | Sep. 30, 2024 10:53
Global Clostridium Diagnostics Market is valued at approximately USD 838.05 million in 2022 and is anticipated to grow with a healthy growth rate of more than 7.10% over the forecast period 2023-2030.
·taiwannews.com.tw·
Clostridium Diagnostics Market Key Trends, Challenges, and Growth Forecasts from 2024 to 2032 | Taiwan News | Sep. 30, 2024 10:53
Difficile-Associated Diarrhea Treatment Market Report 2024: Size, Share, Growth, Trends, Forecast to 2033
Difficile-Associated Diarrhea Treatment Market Report 2024: Size, Share, Growth, Trends, Forecast to 2033
The Business Research Company recently released a comprehensive report on the Global Difficile Associated Diarrhea Treatment Market Size and Trends Analysis with Forecast 2024 2033 This latest market research report offers a wealth of valuable insights and data including global ...
·openpr.com·
Difficile-Associated Diarrhea Treatment Market Report 2024: Size, Share, Growth, Trends, Forecast to 2033
Clostridium difficile in Patients With Cystic Fibrosis
Clostridium difficile in Patients With Cystic Fibrosis
• One hundred seven patients with cystic fibrosis (CF) and 54 other patients with risk factors for Clostridium difficile–associated disease were entered into a bacteriologic study to compare the rate of recovery of C difficile and cytotoxin in feces with occurrence of diarrhea and to investigate...
·jamanetwork.com·
Clostridium difficile in Patients With Cystic Fibrosis
Identification and preclinical evaluation of MMV676558 as a promising therapeutic candidate against Clostridioides difficile - PubMed
Identification and preclinical evaluation of MMV676558 as a promising therapeutic candidate against Clostridioides difficile - PubMed
Clostridioides difficile, a gram-positive, toxin-producing, spore-forming anaerobe, is a major cause of antibiotic-associated diarrhoea. The bacterium's intrinsic drug resistance limits current treatment options to fidaxomicin and vancomycin for initial episodes, with anti-toxin B monoclonal antibod …
·pubmed.ncbi.nlm.nih.gov·
Identification and preclinical evaluation of MMV676558 as a promising therapeutic candidate against Clostridioides difficile - PubMed
FMT Trial Shows Limited Efficacy for C difficile Recurrences
FMT Trial Shows Limited Efficacy for C difficile Recurrences
Study halted due to ineffective results, but the findings still provide valuable insights for future research and improve treatment strategies for those affected by CDI.
·contagionlive.com·
FMT Trial Shows Limited Efficacy for C difficile Recurrences
Why Are Superbugs So Dangerous?
Why Are Superbugs So Dangerous?
Hello, it's Ashleigh coming to you from New York this week where the city is flooded with world leaders for the UN General Assembly. On Thursday the buzz of attention shifted to the “silent pandemic” of antimicrobial resistance. But first...
·bloomberg.com·
Why Are Superbugs So Dangerous?
Publisher Correction: Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020-2022 - PubMed
Publisher Correction: Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020-2022 - PubMed
Publisher Correction: Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020-2022
·pubmed.ncbi.nlm.nih.gov·
Publisher Correction: Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020-2022 - PubMed
Clostridioides difficile Infections in Children: What Is the Optimal Laboratory Diagnostic Method? - PubMed
Clostridioides difficile Infections in Children: What Is the Optimal Laboratory Diagnostic Method? - PubMed
The diagnosis of Clostridioides difficile infection (CDI) in the pediatric population is complicated by the high prevalence of asymptomatic colonization, particularly in infants. Many laboratory diagnostic methods are available, but there continues to be controversy over the optimal laborator …
·pubmed.ncbi.nlm.nih.gov·
Clostridioides difficile Infections in Children: What Is the Optimal Laboratory Diagnostic Method? - PubMed
Efficacy and safety of a preventive strategy against tuberculosis in liver transplantation recipients including the treatment of latent infection with moxifloxacin - PubMed
Efficacy and safety of a preventive strategy against tuberculosis in liver transplantation recipients including the treatment of latent infection with moxifloxacin - PubMed
A preventive strategy based on systematic LTBI screening and moxifloxacin treatment before LT in positive cases appears safe and effective in preventing the development of tuberculosis in LT recipients. However, our findings are limited by a small sample size; thus, larger studies are required to va …
·pubmed.ncbi.nlm.nih.gov·
Efficacy and safety of a preventive strategy against tuberculosis in liver transplantation recipients including the treatment of latent infection with moxifloxacin - PubMed
Which trials do we need? Fidaxomicin plus either intravenous metronidazole or tigecycline versus vancomycin plus either intravenous metronidazole or tigecycline for fulminant Clostridioides difficile infection - PubMed
Which trials do we need? Fidaxomicin plus either intravenous metronidazole or tigecycline versus vancomycin plus either intravenous metronidazole or tigecycline for fulminant Clostridioides difficile infection - PubMed
Which trials do we need? Fidaxomicin plus either intravenous metronidazole or tigecycline versus vancomycin plus either intravenous metronidazole or tigecycline for fulminant Clostridioides difficile infection
·pubmed.ncbi.nlm.nih.gov·
Which trials do we need? Fidaxomicin plus either intravenous metronidazole or tigecycline versus vancomycin plus either intravenous metronidazole or tigecycline for fulminant Clostridioides difficile infection - PubMed
Incubation period of Clostridioides difficile infection in hospitalized patients and long-term care facility residents: a prospective cohort study - PubMed
Incubation period of Clostridioides difficile infection in hospitalized patients and long-term care facility residents: a prospective cohort study - PubMed
Our findings are consistent with the previous studies that suggested the incubation period for CDI is typically less than 1 week and is less than 2 weeks in most cases.
·pubmed.ncbi.nlm.nih.gov·
Incubation period of Clostridioides difficile infection in hospitalized patients and long-term care facility residents: a prospective cohort study - PubMed
'Does this fecal microbiota transplant work?' Quality assurance of capsule based fecal microbiota transplant production - PubMed
'Does this fecal microbiota transplant work?' Quality assurance of capsule based fecal microbiota transplant production - PubMed
The fact that our caFMT compared similarly to the imported caFMT was viewed as a success in terms of quality assurance. Our caFMT had a slightly lower success rates compared to data from other studies, but could be affected by several other factors than our FMT-production methods. A lower success ra …
·pubmed.ncbi.nlm.nih.gov·
'Does this fecal microbiota transplant work?' Quality assurance of capsule based fecal microbiota transplant production - PubMed
Lateral flow immunoassay for simultaneous detection of C. difficile, MRSA, and K. pneumoniae - PubMed
Lateral flow immunoassay for simultaneous detection of C. difficile, MRSA, and K. pneumoniae - PubMed
Mainly performed within a rapid diagnostic tests company, a lateral flow (LF) system using gold nanoparticles (AuNPs) as transducers is presented able to detect three bacteria of interest, of relevance for antimicrobial resistance (AMR): Clostridioides difficile, methicillin-resistant Staphylococcus …
·pubmed.ncbi.nlm.nih.gov·
Lateral flow immunoassay for simultaneous detection of C. difficile, MRSA, and K. pneumoniae - PubMed
Gut Microbial and Metabolic Features Associated With Clostridioides difficile Infection Recurrence in Children - PubMed
Gut Microbial and Metabolic Features Associated With Clostridioides difficile Infection Recurrence in Children - PubMed
Our study suggests that the differing gut microbiota profiles in pediatric CDI patients may contribute to disease recurrence by modulating SCFA concentrations and bile acid profiles. The gut microbiota and metabolite signatures may be used to predict disease recurrence in children with CDI.
·pubmed.ncbi.nlm.nih.gov·
Gut Microbial and Metabolic Features Associated With Clostridioides difficile Infection Recurrence in Children - PubMed
Fecal microbiota spores, live-brpk (VOWST™/VOS) for prevention of recurrent Clostridioides difficile infection - PubMed
Fecal microbiota spores, live-brpk (VOWST™/VOS) for prevention of recurrent Clostridioides difficile infection - PubMed
Clostridioides difficile infection (CDI) is a health crisis comprising a majority of healthcare-associated infections and is now being seen in the community. Persistent dysbiosis despite treatment with standard-of-care antibiotics increases risk of recurrent infections. Fecal microbiota trans …
·pubmed.ncbi.nlm.nih.gov·
Fecal microbiota spores, live-brpk (VOWST™/VOS) for prevention of recurrent Clostridioides difficile infection - PubMed
Advocating for Better Regulatory Rules and Standard of Care for C difficile
Advocating for Better Regulatory Rules and Standard of Care for C difficile
Maryann Webb’s harrowing, personal experience with C diff, along with her professional work with federal agencies has prepared her for a life in advocacy with the Peggy Lillis Foundation. She wants to see the fecal microbiota transplant become more accessible and is working with Congress to make the infection a notifiable infectious disease.
·contagionlive.com·
Advocating for Better Regulatory Rules and Standard of Care for C difficile
Identification and preclinical evaluation of MMV676558 as a promising therapeutic candidate against Clostridioides difficile - PubMed
Identification and preclinical evaluation of MMV676558 as a promising therapeutic candidate against Clostridioides difficile - PubMed
Clostridioides difficile, a gram-positive, toxin-producing, spore-forming anaerobe, is a major cause of antibiotic-associated diarrhoea. The bacterium's intrinsic drug resistance limits current treatment options to fidaxomicin and vancomycin for initial episodes, with anti-toxin B monoclonal antibod …
·pubmed.ncbi.nlm.nih.gov·
Identification and preclinical evaluation of MMV676558 as a promising therapeutic candidate against Clostridioides difficile - PubMed
Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection - PubMed
Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection - PubMed
Clostridioides difficile infection (CDI) is a major cause of healthcare- and antibiotic-associated diarrhea. While fecal microbiota transplantation (FMT) shows promise for recurrent CDI, its mechanisms and long-term safety are not fully understood. Live biotherapeutic products (LBPs) using pre-defin …
·pubmed.ncbi.nlm.nih.gov·
Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection - PubMed